Home Biotechnology Amneal Pharmaceuticals
A

Amneal Pharmaceuticals

Profile managed by Bizz Id
United States 2002

Description

Amneal Pharmaceuticals is a US pharmaceutical company for generic, specialty and biosimilar medicines. Since August 2026 it includes Kashiv BioSciences, which brings biologics development and manufacturing in the US and India. It markets filgrastim, pegfilgrastim and bevacizumab biosimilars in the US and has a biosimilar pipeline in development.

Products

15 products
Abatacept

Biosimilar to Orencia. Immunology. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Abatacept: see suppliers →

Bevacizumab

Brand: Alymsys (bevacizumab-maly). Biosimilar referencing Avastin.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Certolizumab

Biosimilar to Cimzia. Immunology. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Certolizumab: see suppliers →

Denosumab (ref. Prolia)

Brand: Boncresa. Biosimilar to Prolia. Osteoporosis. Vial. Launch undisclosed.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Denosumab (ref. Xgeva)

Brand: Oziltus. Biosimilar to XGEVA. Bone cancer. Vial. Launch undisclosed.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Dulaglutide

Biosimilar to Trulicity. Diabetes. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dulaglutide: see suppliers →

Dupilumab

Biosimilar to Dupixent. Respiratory. In development; expected approval 2030+.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dupilumab: see suppliers →

Filgrastim

Brand: Releuko (filgrastim-ayow). Biosimilar referencing Neupogen. Amneal's first US biosimilar (2022).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Filgrastim: see suppliers →

Guselkumab

Biosimilar to Tremfya. Immunology. In development; expected approval 2030+.

Under development

Finished product (FDF)

Verified on 2026-10-21

Guselkumab: see suppliers →

Nivolumab

Biosimilar to Opdivo. Oncology. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Omalizumab

Biosimilar to XOLAIR. Immunology/Allergy. Prefilled syringe. Not yet approved; estimated approval date.

Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Omalizumab: see suppliers →

Pegfilgrastim

Brand: Fylnetra (pegfilgrastim-pbbk). Biosimilar referencing Neulasta. Launched in the US in 2023.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegfilgrastim: see suppliers →

Pembrolizumab

Biosimilar to Keytruda. Oncology. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Risankizumab

Biosimilar to Skyrizi. Immunology. In development; expected approval 2030+.

Under development

Finished product (FDF)

Verified on 2026-10-21

Risankizumab: see suppliers →

Romiplostim

Biosimilar to Nplate. Hematology. In development; expected approval 2028–2030.

Under development

Finished product (FDF)

Verified on 2026-10-21

Romiplostim: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free